Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 6/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8308748 | 0.85 | ALDH1A1 (0.48) | KMT2AALDH1A1 | |
| SCHEMBL12404088 | 0.84 | BRD4 (0.46) | SMN1; SMN2PTPN2PTPN1PTPN6HPGD | |
| SCHEMBL17158249 | 0.77 | KDM1A (0.49) | SMN1; SMN2PTPN2PTPN1PTPN6STS | |
| SCHEMBL57231 | 0.75 | HPGD (0.62) | SMN1; SMN2PTPN2PTPN1PTPN6HPGD | |
| SCHEMBL6615895 | 0.74 | NPC1 (0.47) | SMN1; SMN2PTPN2PTPN1PTPN6HPGD | |
| SCHEMBL18039817 | 0.74 | PDE4B (0.46) | PTPN2PTPN1PTPN6HPGDSTS | |
| SCHEMBL7311960 | 0.73 | SMN1; SMN2 (0.50) | SMN1; SMN2STSKMT2ANPC1RAB9A | |
| SCHEMBL27851257 | 0.73 | USP2 (0.42) | SMN1; SMN2HPGDRECQLKMT2A | |
| SCHEMBL1119307 | 0.73 | HPGD (0.59) | SMN1; SMN2PTPN2PTPN1PTPN6HPGD | |
| SCHEMBL21996403 | 0.73 | KDM1A (0.39) | SMN1; SMN2PTPN2PTPN1PTPN6HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7727999-B2 | substituted 1,3,8-triaza-spiro[4.5]decan-2-one compounds, used as selective serotonin receptor antagonists, used rfor the treatment of schizophrenia, psychosis, headaches, hypertension, thrombosis, vasospasm, depression, anxiety, sleep disorders and appetite disorders | ACADIA PHARMACEUTICALS INC. (US) | 2010-06-01 | — | — | US | disclosed |
| EP-1461339-B1 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | ACADIA PHARM INC (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20090131418-A1 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | ACADIA PHARAMCEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-7511053-B2 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7402590-B2 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-7351707-B2 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| CN-100372848-C | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARM INC (US) | 2008-03-05 | — | — | CN | disclosed |
| WO-2007124136-A1 | USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS | ACADIA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070161621-A1 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | ACADIA PHARMACEUTICALS (US) | 2007-07-12 | — | — | US | disclosed |
| US-7217719-B2 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20060205710-A1 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. | 2006-09-14 | — | — | US | disclosed |
| US-20060199794-A1 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. | 2006-09-07 | — | — | US | disclosed |
| US-20050256108-A1 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. | 2005-11-17 | — | — | US | disclosed |
| US-6911452-B2 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. (US) | 2005-06-28 | — | — | US | disclosed |
| CN-1612877-A | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARM INC (US) | 2005-05-04 | — | — | CN | disclosed |
| US-20030166928-A1 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256108-A1 | Spiroazacyclic compounds as monoamine receptor modulators | MAOA, MAOB, HTR5A | SMN1; SMN2 3011/4885PTPN2 1442/4885PTPN1 1339/4885 |
| US-20060205710-A1 | Spiroazacyclic compounds as monoamine receptor modulators | MAOA, MAOB, HTR5A | SMN1; SMN2 3011/4885PTPN2 1442/4885PTPN1 1339/4885 |
| US-20090131418-A1 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | MAOA, MAOB, HTR5A | SMN1; SMN2 3011/4885PTPN2 1442/4885PTPN1 1339/4885 |
| US-20030166928-A1 | Spiroazacyclic compounds as monoamine receptor modulators | MAOA, MAOB, HTR5A | SMN1; SMN2 3011/4885PTPN2 1442/4885PTPN1 1339/4885 |
| US-20070161621-A1 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | MAOA, MAOB, HTR5A | SMN1; SMN2 3011/4885PTPN2 1442/4885PTPN1 1339/4885 |
| US-20060199794-A1 | Spiroazacyclic compounds as monoamine receptor modulators | MAOA, MAOB, HTR5A | SMN1; SMN2 3011/4885PTPN2 1442/4885PTPN1 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.